Abstract: Reagents and compositions for use in reactions catalysed by luciferase enzymes, and in particular for use in luciferase-based gene reporter assays are described. The invention also provides methods and compositions for, inter alia, increasing the sensitivity and/or improving the kinetics of luciferase-catalysed reactions.
Abstract: The present invention discloses systems and methods for altering the color of bacterial bioluminescence via a fusion protein complex by fusing Discosoma sp. fluorescent protein mOrange (mOrange) with Vibrio harveyi luciferase. The fusion of mOrange to the N- or C-terminus of either ? or ? subunit of luciferase, via a short peptide linker produces fully active fusion enzymes. The fusion of mOrange to the N-terminus of luciferase ? gives rise to a new 560-nm emission component. The same methodology may be used to alter bacterial bioluminescence color by covalent attachment of other suitable fluorescent proteins or chromophores to luciferase for generating multi-color sensors.
Abstract: Nucleotide and amino acid sequences of luciferase peptides that are encoded by genes within the genome of Arachnocampa (Diptera) are disclosed. Specifically provided are functional ATP-dependent luciferases that catalyze luminescence reactions with emission spectra within the blue portion of the spectrum. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and active subsequences of the enzyme peptides, and methods of identifying modulators and substrates of the luciferase peptides. Methods of assays, including multiple reporter assays utilizing at least two ATP-dependent luciferases are provided.
Type:
Grant
Filed:
August 18, 2006
Date of Patent:
July 24, 2012
Assignee:
Commonwealth Scientific and Industrial Research Organisation
Inventors:
Virginia Leitch, Mira Maria Dumancic, Stephen Charles Trowell, Helen Dacres
Abstract: The present invention provides a mutant beetle luciferase and the like, having mutation in which the amino acid corresponding to valine at position 288 in the amino acid sequence of wild-type Photinus pyralis luciferase is isoleucine, leucine or phenylalanine, mutation in which the amino acid corresponding to leucine at position 376 in the aforementioned sequence is proline, mutation in which the amino acid corresponding to glutamic acid at position 455 in the aforementioned sequence is valine, alanine, serine, leucine, isoleucine or phenylalanine, or mutation in which the amino acid corresponding to glutamic acid at position 488 in the aforementioned sequence is valine, alanine, serine, leucine, isoleucine or phenylalanine, in the amino acid sequence encoding a wild-type beetle luciferase, and characterized in that a luminescence intensity due to a luciferin-luciferase luminescence reaction in a 0.9% by mass NaCl solution is 50% or more of that in a NaCl-free solution.
Type:
Grant
Filed:
June 19, 2017
Date of Patent:
December 1, 2020
Assignee:
DKK-TOA Corporation
Inventors:
Kenichi Noda, Satoshi Yawata, Ai Shimomura
Abstract: A method and kit are provided for enhancing the tolerance of an assay reagent to compounds in an assay sample, the assay reagent including a luciferase enzyme. The method includes contacting the luciferase with a tolerance enhancement agent in an amount sufficient to substantially protect luciferase enzyme activity from interference of the compound and minize interference by at least about 10% relative to an assay not having tolerance enhancement agent.
Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
Type:
Application
Filed:
April 14, 2015
Publication date:
October 22, 2015
Inventors:
Satoshi INOUYE, Yuiko MIURA, Junichi SATO
Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
Type:
Application
Filed:
December 7, 2017
Publication date:
May 3, 2018
Applicant:
JNC CORPORATION
Inventors:
Satoshi INOUYE, Yuiko MIURA, Junichi SATO
Abstract: According to one embodiment, the present invention relates to luciferase derived from Malaysian Luciola firefly, the luciferase having a maximum luminescent wavelength of 580 nm at pH 8, or the luciferase indicating 23.3 times or more of luminescent intensity in comparison to that of Rhodamine 6G.
Type:
Grant
Filed:
August 20, 2012
Date of Patent:
May 13, 2014
Assignees:
Olympus Corporation, Nimura Genetic Solutions Co., Ltd., Perak State Development Corporation
Abstract: Proteins are provided having luciferase activity with lower Km than wild-type luciferases by altering the amino acid residue at position 270 of the wild-type to an amino acid other than glutamate. Greater heat stability than wild-type luciferases while retaining the lower Km is provided by also replacing the glutamate equivalent to that at position 354 of Photinus pyralis luciferase or 356 of Luciola luciferases with an alternative amino acid, particularly lysine and/or the amino acid residue at 215 of Photinus pyralis and 217 of the Luciola species with a hydrophobic amino acid. DNA, vectors and cells that encode for and express the proteins are also provided as are test kits and reagents for carrying out luminescence assays using the proteins of the invention.
Type:
Grant
Filed:
October 1, 1997
Date of Patent:
January 9, 2001
Assignee:
The Secretary of State for Defence in Her Britannic Majesty's
Government of the United Kingdom of Great Britain and Northern
Ireland
Inventors:
David J Squirrell, Christopher R Lowe, Peter J White, James A H Murray
Abstract: A new thermostable luciferase of the following mutant luciferase (a) or (b): (a) a mutant of a wild-type luciferase comprising the amino acid sequence of SEQ ID NO: 1, wherein phenylalanine at position 292 and/or phenylalanine at position 294 in the amino acid sequence of SEQ ID NO: 1 is substituted with another amino acid; or (b) a mutant of a luciferase having 93% or more homology with the amino acid sequence of SEQ ID NO: 1, wherein in the amino acid sequence of the mutant, the amino acid at a site corresponding to position 292 and/or position 294 in the amino acid sequence of SEQ ID NO: 1 is substituted with another amino acid.
Abstract: According to one embodiment, the present invention relates to luciferase derived from Malaysian Luciola firefly, the luciferase having a maximum luminescent wavelength of 580 nm at pH 8, or the luciferase indicating 23.3 times or more of luminescent intensity in comparison to that of Rhodamine 6G.
Type:
Application
Filed:
August 20, 2012
Publication date:
February 14, 2013
Applicants:
OLYMPUS CORPORATION, PERAK STATE DEVELOPMENT CORPORATION, NIMURA GENETIC SOLUTIONS CO., LTD.
Abstract: A new thermostable luciferase of the following mutant luciferase (a) or (b): (a) a mutant of a wild-type luciferase comprising the amino acid sequence of SEQ ID NO: 1, wherein phenylalanine at position 292 and/or phenylalanine at position 294 in the amino acid sequence of SEQ ID NO: 1 is substituted with another amino acid; or (b) a mutant of a luciferase having 93% or more homology with the amino acid sequence of SEQ ID NO: 1, wherein in the amino acid sequence of the mutant, the amino acid at a site corresponding to position 292 and/or position 294 in the amino acid sequence of SEQ ID NO: 1 is substituted with another amino acid.
Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
Type:
Application
Filed:
May 6, 2019
Publication date:
August 22, 2019
Applicant:
JNC CORPORATION
Inventors:
Satoshi INOUYE, Yuiko MIURA, Junichi SATO
Abstract: A novel luciferase that distinct from conventional luciferase has been desired. A luciferase mutant comprising the amino acid sequence of SEQ ID NO: 2 substituted at tyrosine at the position of 138, and at least 3 positions selected from the group consisting of isoleucine at the position of 90, proline at the position of 115, glutamine at the position of 124, and asparagine at the position of 166.
Abstract: A method and kit is provided for enhancing the tolerance of an assay reagent to compounds in an assay sample, the assay reagent including a luciferase enzyme. The method includes contacting the luciferase with a tolerance enhancement agent in an amount sufficient to substantially protect luciferase enzyme activity from interference of the compound and minize interference by at least about 10% relative to an assay not having tolerance enhancement agent.
Type:
Application
Filed:
December 23, 2003
Publication date:
February 3, 2005
Inventors:
Erika Hawkins, James Cali, Samuel Ho, Martha O'Brien, Richard Somberg, Robert Bulleit, Keith Wood
Abstract: A polynucleotide encoding a secreted form of wild type Renilla luciferase. Also provided is a polynucleotide encoding a secreted modified form of wild type Renilla luciferase. Additionally, the polypeptides encoded by the polynucleotides of the present invention and uses of the polynucleotides and polypeptides of the present invention in biological assays. Also, a stable mammalian packaging cell line which produces retroviruses carrying a polynucleotide encoding a secreted Renilla luciferase.
Abstract: Disclosed is a purified luciferase and a method for making it. The luciferase is obtained from Luciola cruciata. The luciferase has a pH range for stabililty of 6.5-9.0 and a optimum pH range of 8.0-9.5. The enzyme does not act on ADP, CTP, UTP and GTP.
Abstract: There is provided a process of inducing luminescent emission from a luciferase bioluminescent reaction particularly useful in binding assays. A luciferase bioluminescent combination, together with an inactive, caged trigger compound such as a cofactor, is subjected to photonic radiation, so as to release the trigger compound in active form, and thereby cause substantially instantaneous reaction of the active trigger compound so released with the luciferase combination, to induce photonic emission which can be detected and measured.
Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
Type:
Grant
Filed:
April 14, 2015
Date of Patent:
January 16, 2018
Assignee:
JNC CORPORATION
Inventors:
Satoshi Inouye, Yuiko Miura, Junichi Sato